Modernizing USA's Medicare and Medicaid could save the federal government $542 billion over next decade; report

11 January 2013

The US federal government, confronting an enormous fiscal challenge, could save up to $542 billion in Medicare and Medicaid spending over the next 10 years through a proven “third strategy” for modernizing health care and improving patient outcomes, according to a new report by UnitedHealth Group’s (NYSE: UNH) Center for Health Reform & Modernization.

The current national debate about Medicare and Medicaid has largely centered on either cutting patient benefits or cutting provider payments. This report analyzes a third strategy: unlocking savings through applying best practices for improved prevention, care coordination and payment reform to Medicare and Medicaid. Around 75% of the nation’s roughly $1 trillion of Medicare and Medicaid annual spending still relies on outdated indemnity-style benefits and siloed fee-for-service provider reimbursement.

“Real world evidence now shows that Medicare and Medicaid can be modernized, helping deal with the massive fiscal threat the country faces, in a way that is a win-win for people who depend on these critical programs, and for the taxpayers who fund them,” said Simon Stevens, chairman of the UnitedHealth Center for Health Reform & Modernization, executive vice president of UnitedHealth Group, and one of the paper’s authors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical